Wedbush Rates Cullinan Therapeutics (CGEM) buy, $37 Price Target
Wedbush's Robert Driscoll reaffirms a buy rating for CGEM, targeting $37, as shares currently trade at $12.97, a 185.27% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wedbush rated Cullinan Therapeutics, Inc. ($CGEM) "buy" with a $37 price target on June 11, 2026.
Since the rating, $CGEM is up 15.8% after 1 week, up 37.7% after 1 month and down 0.4% to date (from the $12.98 close on Jun 11, 2026).
CGEM
Cullinan Therapeutics, Inc.
Key Points
- On June 11, 2026, Wedbush reiterated a buy rating on CGEM with a target price of $37, indicating a significant upside from the current price of $12.97.
- CGEM operates in the healthcare sector, focusing on developing therapies for autoimmune diseases and cancer, with shares currently trading significantly below their 52-week high of $23.19.
- Analysts are largely optimistic about CGEM, as evidenced by an average target price of $33.55 from 11 analysts, reflecting a strong buy consensus.
Get $CGEM trade alerts by text
We text you when insiders, Congress or big funds trade $CGEM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cullinan Therapeutics, Inc. alert may contain errors. Disclosures
Wedbush Maintains Bullish Outlook on CGEM
Wedbush's Robert Driscoll has reiterated a buy rating for CGEM (NasdaqGS: CGEM) with a target price of $37. As of June 11, 2026, CGEM shares are trading at $12.97. This suggests a potential upside for investors, given the target price is well above the current market value.
Analysts Set New Price Targets
Wedbush's reaffirmation comes as CGEM continues to navigate its clinical-stage developments. The stock trades significantly below its 52-week high of $23.19, which may indicate potential for recovery, especially as the company progresses with its innovative therapies for autoimmune diseases and cancer.
Other firms have also shown support for CGEM. On October 2, 2026, HC Wainwright & Co. reiterated their buy rating with a target of $35. Just weeks earlier, on September 25, they had maintained the same rating but increased their target from $30 to $35. BTIG has also been bullish, maintaining a buy rating with targets of $40 and $39 on September 25 and July 29, respectively. Such consistent positive ratings suggest a solid consensus around CGEM's future prospects.
Stock Performance and Future Outlook
CGEM's current stock price of $12.97 is significantly lower than past trading highs, making it an interesting option for growth-seeking investors. The stock's performance suggests it may be undervalued, especially in light of the analysts' price targets which average around $33.55. Investors will be closely watching how the company performs as it progresses through its clinical trials and approaches its next earnings report on November 14, 2026.
$CGEM price target
Cullinan Therapeutics, Inc. daily closes and this analyst's $37 target. Not advice.
What CGEM Does
Cullinan Therapeutics, Inc. focuses on developing therapies for autoimmune diseases and cancer. The company is involved in several clinical trials, including treatments aimed at addressing significant medical needs in these areas. With its strategic partnerships and a talented team, CGEM seeks to advance its innovative pipeline in the biopharmaceutical sector.
What to Watch at CGEM
As CGEM approaches its next earnings date on November 14, 2026, all eyes will be on the results of its clinical trials and any announcements that could impact its stock price. The reiteration of bullish ratings from analysts bodes well for investor sentiment, but the upcoming earnings will provide more clarity on the company's performance. Remember, the ratings and targets discussed reflect the analysts' views as of June 11 and may shift as new information becomes available.
Related Filing Alerts
Source: Wedbush's rating change on $CGEM (Jun 11, 2026). Written by software, not financial advice. How we make alerts